SYRE
Aeglea BioTherapeutics Inc

2,054
Mkt Cap
$2.41B
Volume
569,338.00
52W High
$35.31
52W Low
$10.91
PE Ratio
-13.84
SYRE Fundamentals
Price
$30.14
Prev Close
$31.05
Open
$30.42
50D MA
$28.79
Beta
1.70
Avg. Volume
852,398.23
EPS (Annual)
-$3.18
P/B
4.03
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $460,200.00 in Stock
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the company's stock in a transaction dated Friday, January 2nd. The stock was sold at an average...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the firm's stock in a transaction on Friday, January 2nd. The shares were sold at an average price of...
MarketBeat·2d ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5% - Time to Sell?
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5% - What's Next...
MarketBeat·7d ago
News Placeholder
Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors
Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors There are just nine days left in the year, and this year has flown by. We've delivered readers a steady stream of 2026...
Zero Hedge·16d ago
News Placeholder
Citigroup Upgrades Spyre Therapeutics (NASDAQ:SYRE) to "Strong-Buy"
Citigroup upgraded Spyre Therapeutics to a "strong-buy" rating in a research report on Wednesday...
MarketBeat·21d ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at Mizuho
Mizuho upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a report on Thursday...
MarketBeat·21d ago
News Placeholder
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from Analysts
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has earned an average recommendation of "Buy" from the nine analysts that are covering the company, MarketBeat.com reports. One analyst has...
MarketBeat·26d ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week High - Should You Buy?
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month High - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 7.2% - Still a Buy?
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 7.2% - What's Next...
MarketBeat·1mo ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction dated Monday, December 1st. The stock was sold at an...
MarketBeat·1mo ago
<
1
2
...
>

Latest SYRE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.